FREE TRAINING /

Regulatory Pathways for Combination Products Under the EU MDR

Tina Amini
7 minutes 1 seconds

Lesson Overview

This video, presented by Tina Amini (Director of Medtech Combinations), explains the regulatory pathway for combination products under the EU MDR.

Regulatory Classification of Combination Products

  • The EU does not have a specific “combination product” classification.
  • Instead, products are regulated as either medicinal products or medical devices.
  • Primary Mode of Action (PMOA) determines classification:
    • Medical Device: Works through physical, simple chemical, or digital means.
    • Medicinal Product: Works through pharmacological, metabolic, or immunological action.

Single Integral Drug-Device Combinations Regulated as Medical Devices

  • These are devices that incorporate an ancillary medicinal substance.
  • MDR Annex VIII, Rule 14 applies:
    • Class III (highest risk classification) for devices with medicinal components.
    • The rule omits the phrase “liability to act” meaning all such devices fall under Class III.

Certification Process for Medical Devices with Medicinal Substances

  • The manufacturer applies to a Notified Body, which assesses:
    • Quality Management System (QMS) and technical documentation.
    • Usefulness of the medicinal substance in the device.
  • The Notified Body must consult either:
    • EU Competent Authorities or EMA (European Medicines Agency).
    • EMA consultation is required if the substance comes from human blood/plasma or falls under Regulation 726/2004.
  • Timelines: The consultation process takes at least 210 days, excluding pauses for additional queries.
  • Final Decision:
    • If the opinion is positive, the Notified Body issues certification.
    • If the opinion is negative, certification cannot be granted.

Impact of Article 117 on Drug-Device Combinations Regulated as Medicinal Products

  • Article 117 of MDR amends the Medicinal Product Directive.
  • Marketing Authorization Applications (MAAs)must include:
    • Results of conformity assessment OR
    • Notified Body certification (CE marking) OR
    • Notified Body opinion report if CE marking is unavailable.
  • If the device part is not CE marked, pharmaceutical/biotech companies must:
    • Engage with a Notified Body to obtain a Notified Body Opinion (NBOp) on the device component.
    • Include the NBOp in the marketing authorisation dossier submitted to the EMA.